TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22456429

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg intravenous, four doses every 3 weeks, then every 12 weeks for clinically stable patients)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg intravenous)
Number of subjects: 72
Study: 22456658

Group type: EXPERIMENTAL
Intervention: Directive control
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nondirective control
Number of subjects: 330
Study: 22456659

Group type: EXPERIMENTAL
Intervention: BAT+ (19 patients)
Number of subjects: 32
Study: 22456661

Group type: EXPERIMENTAL
Intervention: Multiple-criteria model (≥ 2 of 3 abnormal ferritin < 12 μg/L, soluble transferrin receptor (TfR) > 8.3 mg/L, zinc protoporphyrin (ZP) > 80 μmol/mol)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Abnormal ferritin alone
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Abnormal TfR alone
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Abnormal ZP alone
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: TfR/ferritin index (ID > 500)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Adjusted values for low ferritin and elevated TfR/ferritin index
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: TfR
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis for TfR
Number of subjects: 680
Study: 22456662

Group type: EXPERIMENTAL
Intervention: Zinc depletion (10 d, 0.3 mg Zn/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zinc repletion (7 d, 29.5 mg Zn/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zinc acclimation (7 d, 10.4 mg Zn/d)
Number of subjects: 9
Study: 22456695

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 174

Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Comparison of OGTT to FPG and HbA1c
Number of subjects: 174
Study: 22457087

Group type: EXPERIMENTAL
Intervention: Positive fluid balance (FB)
Number of subjects: 100
Study: 22457244

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 0
Study: 22457291

Group type: EXPERIMENTAL
Intervention: S. epidermidis isolates from cultures
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Disseminated clones
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: VAD-related infections
Number of subjects: 75
Study: 22457855

Group type: EXPERIMENTAL
Intervention: Gluten-free diet adherence
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Patient satisfaction with diagnosis
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Dietary lapses and negative attitude
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Doctor-patient communication
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Support for young and asymptomatic patients
Number of subjects: 698
Study: 22458289

Group type: EXPERIMENTAL
Intervention: Testing for sexually transmitted infections (STIs) including chlamydia, trichomonas, and gonorrhea
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Demographic factors and sexual behavior analysis
Number of subjects: 245
Study: 22458427

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study: 22461458

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapies based on identified mutations and alterations in protein expression
Number of subjects: 0
Study: 22465214

Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (MCT)
Number of subjects: 219
Study: 22465288

Group type: EXPERIMENTAL
Intervention: Mobile phone-based heart failure telemonitoring system
Number of subjects: 100
Study: 22465355

Group type: EXPERIMENTAL
Intervention: Newer commercial EHR with robust clinical decision support (CDS) for e-prescribing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Older locally developed EHR with minimal clinical decision support (CDS) for e-prescribing
Number of subjects: 19
Study: 22465364

Group type: EXPERIMENTAL
Intervention: Subconjunctival sirolimus (30 μL, 1320 μg)
Number of subjects: 5
Study: 22466348

Group type: EXPERIMENTAL
Intervention: Mifepristone (300-1200 mg daily)
Number of subjects: 50
Study: 22467666

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg on day 1) plus Trastuzumab (8 mg/kg on day 1 of cycle 1, 6 mg/kg on day 1 of each subsequent cycle) plus Capecitabine (1,000 mg/m2 twice daily, days 1-14) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Bevacizumab, Trastuzumab, and Capecitabine combination therapy.
Number of subjects: 88
Study: 22469445

Group type: EXPERIMENTAL
Intervention: Rescue medication use
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Emergency department visits
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Unscheduled physician visits
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Positive allergen skin test results
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Transportation problems
Number of subjects: 109
Study: 22469621

Group type: EXPERIMENTAL
Intervention: Chronic autonomic failure patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ganglionic blocker trimethaphan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sedentary healthy controls
Number of subjects: 10
Study: 22469860

Group type: EXPERIMENTAL
Intervention: 2010-11 TIV (1 or 2 doses)
Number of subjects: 207
Study: 22470077

Group type: EXPERIMENTAL
Intervention: Standard Operating Procedures (SOPs)
Number of subjects: 1637
Study: 22471287

Group type: EXPERIMENTAL
Intervention: CsA, mycophenolate sodium (MPA) plus corticosteroids (n = 6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CsA and everolimus plus corticosteroids (n = 8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CsA-free (CsA(free)) receiving everolimus, MPA and corticosteroids (n = 6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CsA (reg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increase in CCR5(+) CXCR3(+) co-expressing CD4(+) FoxP3(-) T cells
Number of subjects: 20
Study: 22471378

Group type: EXPERIMENTAL
Intervention: Multi-component rehabilitation intervention including online monitoring of function with feedback and self-management workshops
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 22471422

Group type: EXPERIMENTAL
Intervention: Acupuncture treatments
Number of subjects: 8
Study: 22471947

Group type: EXPERIMENTAL
Intervention: Offline Positron-Emission-Tomography (PET) quality assurance
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: In-vivo verification
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Site-specific patient-population information
Number of subjects: 240
Study: 22472035

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (12 × 3 Gy E to 18 × 3 Gy E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Number of subjects: 0
Study: 22474060

Group type: EXPERIMENTAL
Intervention: Desmoteplase 90 μg/kg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Desmoteplase 125 μg/kg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Desmoteplase (pooled data from DIAS, DEDAS, and DIAS-2)
Number of subjects: 179
Study: 22475206

Group type: EXPERIMENTAL
Intervention: lanreotide treatment for 6 months
Number of subjects: 0
Study: 22475563

Group type: EXPERIMENTAL
Intervention: Removal of all dental amalgam restorations and replacement with other dental restorative materials.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference group (healthy blood donors matched for age and gender).
Number of subjects: 20
Study: 22476554

Group type: EXPERIMENTAL
Intervention: rAHF-PFM (Advate®)
Number of subjects: 55
Study: 22476856

Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg/day
Number of subjects: 139
Study: 22480772

Group type: EXPERIMENTAL
Intervention: Adalimumab induction therapy (160 mg/80 mg at Weeks 0/2), followed by 40 mg every other week for up to 20 weeks (40 mg weekly for flares/non-response after Week 12)
Number of subjects: 945
Study: 22481227

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2-PS(opt)
Number of subjects: 12
Study: 22483191

Group type: EXPERIMENTAL
Intervention: E-test method applied directly on bronchoalveolar lavage (BAL) samples
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microbroth dilution approach (control method)
Number of subjects: 20
Study: 22483327

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization (IR) defined by residual SYNTAX score (rSS) >0
Number of subjects: 2686

Group type: COMPARATOR
Intervention: Complete revascularization (CR) defined by residual SYNTAX score (rSS) = 0
Number of subjects: 2686

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (rSS) >8.0 after PCI
Number of subjects: 2686

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (rSS) as a predictor
Number of subjects: 2686
Study: 22483418

Group type: EXPERIMENTAL
Intervention: Radial artery pulse wave analysis (PWA)
Number of subjects: 531
Study: 22483738

Group type: EXPERIMENTAL
Intervention: Hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent temozolomide (TMZ)
Number of subjects: 24
Study: 22484295

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV) 7, PCV10, PCV13
Number of subjects: 8261
Study: 22487286

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) in minority patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: National survey data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic literature review
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prospective cohort analysis
Number of subjects: 0
Study: 22490331

Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation (autoSCT)
Number of subjects: 169
Study: 22490397

Group type: EXPERIMENTAL
Intervention: QuickOpt(TM) optimization method
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard echocardiographic optimization
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Comparison of AVTI achieved at optimal settings
Number of subjects: 101
Study: 22490570

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with taxane therapy (docetaxel or paclitaxel)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with taxane therapy
Number of subjects: 202
Study: 22491018

Group type: EXPERIMENTAL
Intervention: Tocilizumab, a humanized monoclonal antibody targeting the IL-6 receptor
Number of subjects: 1683
Study: 22491195

Group type: EXPERIMENTAL
Intervention: CCFSw (Composite Cerebellar Functional Severity Score with the writing test)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: SARA (Scale for the Assessment and Rating of Ataxia)
Number of subjects: 226
Study: 22491406

Group type: EXPERIMENTAL
Intervention: POD-Bonferroni
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: POD k-FWER
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: POD-FDR
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: POD k-FWER with retinal height change ≥50 μm
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TCA-liberal
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TCA-moderate
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TCA-conservative
Number of subjects: 167
Study: 22491731

Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3
Number of subjects: 61
Study: 22491798

Group type: EXPERIMENTAL
Intervention: Carboplatin and trientine
Number of subjects: 5
Study: 22491916

Group type: EXPERIMENTAL
Intervention: Intravitreal ketorolac (4 mg)
Number of subjects: 10
Study: 22491953

Group type: EXPERIMENTAL
Intervention: Lung protective mechanical ventilation (adherence measured by ventilator settings)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Lung protective mechanical ventilation (50% adherence)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Lung protective mechanical ventilation (100% adherence)
Number of subjects: 485
Study: 22493293

Group type: EXPERIMENTAL
Intervention: First salvage chemotherapy (n = 224)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Second salvage chemotherapy (n = 82)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: First salvage chemotherapy after relapse post-SCT (n = 48)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Overall survival after relapse
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: High rate of stem cell transplantation (SCT)
Number of subjects: 547
Study: 22493299

Group type: EXPERIMENTAL
Intervention: Pomalidomide in combination with weekly dexamethasone (Pom/dex)
Number of subjects: 33
Study: 22494019

Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study: 22494428

Group type: EXPERIMENTAL
Intervention: Collaborative-care management program
Number of subjects: 3296

Group type: EXPERIMENTAL
Intervention: Collaborative-care management program (pharmacotherapy and combination trials)
Number of subjects: 3296

Group type: EXPERIMENTAL
Intervention: Collaborative-care management program (psychotherapy and combination trials)
Number of subjects: 3296
Study: 22494861

Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial infarction (PMI)
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: PMI
Number of subjects: 1188
Study: 22496496

Group type: EXPERIMENTAL
Intervention: Furosemide (25 mg iv infusion)
Number of subjects: 16
Study: 22497915

Group type: EXPERIMENTAL
Intervention: 0·12% chlorhexidine digluconate
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (oral care without antiseptic)
Number of subjects: 74
Study: 22498112

Group type: EXPERIMENTAL
Intervention: Cetuximab added to chemotherapy
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: ECOG PS 0
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Asians
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Metastases to one site
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Age (<65 years)
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: ECOG PS
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Region
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Tumor histology
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Number of organs involved
Number of subjects: 1125
Study: 22499072

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined pCLE and NBI
Number of subjects: 36
Study: 22499613

Group type: EXPERIMENTAL
Intervention: (18)F-RGD-K5
Number of subjects: 7
Study: 22499837

Group type: EXPERIMENTAL
Intervention: Treatment with lower and higher doses of pyrimethamine with sulfadizine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: NE-II serotype
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Type II and NE-II infections
Number of subjects: 193
Study: 22500948

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo/active comparator
Number of subjects: 4
Study: 22503162

Group type: EXPERIMENTAL
Intervention: Pregabalin (75-300 mg BID)
Number of subjects: 1206
Study: 22503160

Group type: EXPERIMENTAL
Intervention: Rey Auditory Verbal Learning Task total in CN subjects at 36 months
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating scale sum of boxes in MCI
Number of subjects: 499
Study: 22503395

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Primary surgery treatment (PST)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: NACT responders
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: NACT in stage IB2
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: NACT for patients with stage IB tumours of 2-5 cm
Number of subjects: 707
Study: 22503658

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 22504925

Group type: EXPERIMENTAL
Intervention: Lenalidomide, cyclophosphamide, and dexamethasone (CRd)
Number of subjects: 35
Study: 22504934

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab tiuxetan at two dose levels (22 and 30 MBq/kg) combined with reduced intensity conditioning (RIC) using fludarabine, melphalan, and alemtuzumab followed by allogeneic hematopoietic cell transplantation (HCT).
Number of subjects: 20
Study: 22506003

Group type: EXPERIMENTAL
Intervention: CPR patients after ROSC
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 17

Group type: COMPARATOR
Intervention: Patients after cardiac surgery
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CPR patients after ROSC (6 hours post-admission)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CPR patients after ROSC (subsequent time points)
Number of subjects: 17
Study: 22506623

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 or 10 mg once daily
Number of subjects: 21
Study: 22506949

Group type: EXPERIMENTAL
Intervention: Implementation of EFIC regulations in the RAMPART trial
Number of subjects: 0
Study: 22507624

Group type: EXPERIMENTAL
Intervention: TNF-308 GA genotype
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: TNF-863 CA genotype
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: TNF-863 A carrier status
Number of subjects: 490
Study: 22508412

Group type: EXPERIMENTAL
Intervention: Three doses of a monovalent pediatric HBV vaccine (10 μg of HBsAg)
Number of subjects: 0
Study: 22508715

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 15
Study: 22508772

Group type: EXPERIMENTAL
Intervention: apremilast 20 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: apremilast (both doses)
Number of subjects: 16
Study: 22508812

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline-taxane-based chemotherapy
Number of subjects: 6377
Study: 22508956

Group type: EXPERIMENTAL
Intervention: Multimodal intervention involving an interview about rehabilitation needs with a rehabilitation coordinator, information from the hospital to the GP about individual needs for rehabilitation, and encouragement for the GP to contact the patient.
Number of subjects: 955

Group type: COMPARATOR
Intervention: Control group (usual procedures)
Number of subjects: 955
Study: 22508957

Group type: EXPERIMENTAL
Intervention: Online adverts for CBT
Number of subjects: 3868

Group type: COMPARATOR
Intervention: No adverts for CBT
Number of subjects: 3868
Study: 22509296

Group type: EXPERIMENTAL
Intervention: ICU eligibility as assessed by ED and ICU physicians
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Six-month mortality
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Functional status at six months
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Variability of ICU eligibility rates
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Association between ICU eligibility and outcomes
Number of subjects: 2646
Study: 22509859

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 30)
Number of subjects: 0
Study: 22510871

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg IV every 3 weeks, median 8 cycles; range, 1-16)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 25
Study: 22511402

Group type: EXPERIMENTAL
Intervention: RX Herculink Elite Renal Stent System (Abbott Vascular)
Number of subjects: 202
Study: 22511404

Group type: EXPERIMENTAL
Intervention: PTFE grafts for MHV reconstruction
Number of subjects: 262

Group type: COMPARATOR
Intervention: Cryopreserved iliac veins
Number of subjects: 262

Group type: COMPARATOR
Intervention: Iliac arteries
Number of subjects: 262

Group type: COMPARATOR
Intervention: Aortas
Number of subjects: 262

Group type: COMPARATOR
Intervention: Vein segment 5
Number of subjects: 262
Study: 22511492

Group type: EXPERIMENTAL
Intervention: lenalidomide/dexamethasone treatment after nine cycles
Number of subjects: 47

Group type: COMPARATOR
Intervention: baseline (before treatment)
Number of subjects: 47
Study: 22511498

Group type: EXPERIMENTAL
Intervention: Rituximab, fludarabine and mitoxantrone followed by 2-monthly rituximab maintenance
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Rituximab pharmacokinetics
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Rituximab C(trough)
Number of subjects: 29
Study: 22512824

Group type: EXPERIMENTAL
Intervention: Casein protein
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 16
Study: 22512844

Group type: EXPERIMENTAL
Intervention: Focal therapy using high-intensity focused ultrasound delivered to all known cancer lesions with a margin of normal tissue.
Number of subjects: 42
Study: 22514241

Group type: EXPERIMENTAL
Intervention: Male subjects
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Risk factors for male subjects
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Risk factors for female subjects
Number of subjects: 737
Study: 22514617

Group type: EXPERIMENTAL
Intervention: RDT-positive children treated with ACT
Number of subjects: 391

Group type: COMPARATOR
Intervention: RDT-negative children (non-malaria)
Number of subjects: 391
Study: 22515681

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 40